Loading...
XNAS
LSTA
Market cap29mUSD
Jul 09, Last price  
3.24USD
1D
0.78%
1Q
-35.43%
Jan 2017
-92.38%
Name

Lisata Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:LSTA chart
P/E
—
P/S
173.29
EPS
—
Div Yield, %
—
Shrs. gr., 5y
53.21%
Rev. gr., 5y
25.25%
Revenues
170k
-83.00%
45,724231,66483,54111,565,00069,821,00010,050,00014,330,00014,669,00017,939,00022,488,00035,284,00000000001,000,000170,000
Net income
-17m
L-17.01%
-6,051,000-10,445,473-9,242,071-26,171,000-23,306,000-47,134,000-54,782,000-38,981,000-54,873,000-80,886,000-32,656,00022,979,000-16,167,000-20,101,000-8,150,000-27,466,000-54,225,000-20,840,000-19,985,000-16,586,000
CFO
-16m
L-17.60%
-3,638,831-6,132,424-4,732,165-8,648,022-8,476,699-20,927,994-13,852,518-27,101,693-46,895,238-39,258,331-23,667,682-20,875,882-19,986,000-18,882,000-8,823,000-22,245,000-21,170,000-20,032,000-19,356,000-15,949,000
Dividend
Oct 28, 20130.0021 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
URL
https://www.lisata.com/
IPO date
Nov 03, 1995
Employees
27
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT